Q-omics provides the consensus-scored RDH14 profile across patient tissues and cancer cell-line models. RDH14 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, RDH14 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, RDH14 RNA expression shows 18,973 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRP, HNSC, and ACC as cancer lineages where RDH14 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RDH14 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RDH14 survival associations across molecular data types. RDH14 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (2) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RDH14 RNA expression–survival associations across cancer types. High RDH14 expression shows unfavorable associations in KIRP, UVM, LGG, LIHC and HNSC, but favorable associations in KIRC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for RDH14 RNA expression.
This table summarizes RDH14 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for RDH14. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RDH14 shows lower tumor expression in THCA and KICH and higher tumor expression in HNSC, LIHC, KIRC and BRCA. The HNSC box plot shows higher RDH14 RNA expression in tumor versus normal tissue (log2 FC = +0.629, t-test p < 0.001).
This table shows molecular features associated with RDH14 in patient tissues and cancer cell lines. In patient samples, RDH14 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, RDH14 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Leukemia.
